Carbinoxamine
An antihistamine of the ethanolamine class that blocks H1 receptors to relieve allergy symptoms such as runny nose, sneezing, and itching. It also has sedative properties that can help with sleep disruption caused by allergies. It is used in adults and children for relief of upper respiratory allergy symptoms.
Peso Molecular
290,7900 g/mol
LogP
2,90
TPSA
25,40 Ų
Regra dos 5 de Lipinski
Aprovado
Mecanismo de Ação
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
CN(C)CCOC(c1ccc(Cl)cc1)c1ccccn1
InChI
InChI=1S/C16H19ClN2O/c1-19(2)11-12-20-16(15-5-3-4-10-18-15)13-6-8-14(17)9-7-13/h3-10,16H,11-12H2,1-2H3
Molecular Formula
C16H19ClN2O
HBD / HBA
- / 3
Ligações Rotacionáveis
6
Átomos Pesados
20
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
An antihistamine of the ethanolamine class that blocks H1 receptors to relieve allergy symptoms such as runny nose, sneezing, and itching. It also has sedative properties that can help with sleep disruption caused by allergies. It is used in adults and children for relief of upper respiratory allergy symptoms.
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
Yes, Carbinoxamine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL864. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 2564. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="carbinoxamine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/carbinoxamine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/carbinoxamine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/carbinoxamine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="carbinoxamine"></drugfyi-drug>